Poland· PL-100520467
Skyrizi
A risankizumab product containing risankizumabum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Risankizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC18 (risankizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Risankizumab · ATC L04AC18
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of risankizumab costs, country by country.
Normalised to the WHO defined daily dose (1.67 mg), the median price runs from $0.035 in France to $26.21 in Switzerland — a ×755 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Risankizumab · price per daily dose (1.67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$26.21
- FR France$0.035
The record
At a glance
URPL (Poland)- Active substance
- Risankizumabum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- L04AC18
- ATC class
- Risankizumab
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for risankizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Risankizumab · interactions on record
75 records
- 27 severe
- 41 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Risankizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomSkyrizi 150mg/1ml solution for injection pre-filled pensAbbVie Ltd
- CzechiaSKYRIZIAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainSKYRIZI 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADAAbbvie Deutschland Gmbh & Co. Kg
- IcelandSkyriziAbbVie Deutschland GmbH & Co. KG
- SwedenSkyrizi 150 mg Injektionsvätska, lösning i förfylld injektionspennaAbbVie Deutschland GmbH & Co KG
- BelgiumSkyrizi 150 mgAbbVie Deutschland
- NorwaySkyriziAbbVie Deutschland GmbH & Co
- United StatesSkyriziAbbVie Inc.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Skyrizi
- Iceland · Skyrizi
- Liechtenstein · Skyrizi
- Norway · Skyrizi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb4d3d0d-a019-4fe0-bc43-d5a19862ee83 GET /v1/drugs/cb4d3d0d-a019-4fe0-bc43-d5a19862ee83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "150 mg",
"packaging": "Rpz ¦ EU/1/19/1361/003 ¦ 142794\n1 amp.-strzyk. 1 ml",
"substance": "Risankizumabum 150 mg/ml",
"common_name": "Risankizumabum",
"pl_product_id": "100520467",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about risankizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.